oncomed
Contract development and manufacturing organization (CDMO) focused on aseptic manufacturing and fill–finish of sterile injectable medicines (small molecules and biologics). Provides end-to-end services from formulation and clinical-batch production to commercial scale-up, including pre-filled syringes, vials and cartridges, lyophilization, single-use processing and containment for high-potency APIs. Operates a regulated quality system compliant with EU GMP/ICH/WHO and is audited by national and international regulators.
Industries
Nr. of Employees
medium (51-250)
oncomed
Patents
Products
Pre-filled syringe manufacturing line (Linka 3)
Dedicated commercial filling line for pre-filled syringes with dual-filling technology and automated inspection; commissioned and validated for high‑volume production.
Stationary formulation kettle K1 (1500 L)
1500 L stationary formulation vessel implemented to support centralized formulation workflows and bulk transfer to production lines.
Wastewater treatment unit (WWT)
On-site wastewater treatment system for decontamination and treatment of production effluents with validated testing and monitoring.
Pre-filled syringe manufacturing line (Linka 3)
Dedicated commercial filling line for pre-filled syringes with dual-filling technology and automated inspection; commissioned and validated for high‑volume production.
Stationary formulation kettle K1 (1500 L)
1500 L stationary formulation vessel implemented to support centralized formulation workflows and bulk transfer to production lines.
Wastewater treatment unit (WWT)
On-site wastewater treatment system for decontamination and treatment of production effluents with validated testing and monitoring.
Services
Development, formulation, clinical-batch production, aseptic fill–finish and commercial manufacturing for small molecules and biologics.
Aseptic filling with isolator/RABS integration, packaging and automated inspection for syringe, vial and cartridge formats.
Formulation optimization, centralized bulk preparation and transfer to production lines, supporting clinical and commercial campaigns.
In‑house QC laboratory testing, analytical method development/qualification and batch release testing.
Equipment and line qualification, FAT and SAT execution, and validation documentation for new production lines.
Containment strategies, single‑use integration and operator protection procedures for toxic and high‑potency drug processing.
Development, formulation, clinical-batch production, aseptic fill–finish and commercial manufacturing for small molecules and biologics.
Aseptic filling with isolator/RABS integration, packaging and automated inspection for syringe, vial and cartridge formats.
Formulation optimization, centralized bulk preparation and transfer to production lines, supporting clinical and commercial campaigns.
In‑house QC laboratory testing, analytical method development/qualification and batch release testing.
Equipment and line qualification, FAT and SAT execution, and validation documentation for new production lines.
Containment strategies, single‑use integration and operator protection procedures for toxic and high‑potency drug processing.
Expertise Areas
- Aseptic fill–finish for sterile injectables
- High‑volume syringe manufacturing and commercial scale-up
- Containment and handling of high‑potency/cytotoxic APIs
- Formulation development and centralized bulk formulation
Key Technologies
- Aseptic filling and isolator systems
- Restricted access barrier systems (RABS)
- Dual-head/dual-filling technology
- Automated visual inspection systems
News & Updates
Company representatives presented site developments and participated in the DCAT Member Company Announcement Forum and DCAT Week networking.
Company participation at the CPHI industry conference and exhibition.
Company participation at BIO International Convention 2025.
Project delivering formulation, process development and prototype clinical batch for an oncology drug in collaboration with a university and public funding.
Summary of technical and project milestones in 2023 including new syringe line installation, RABS implementation, FAT and mock-up activities.
Selected as a Top 10 finalist in FOYA 2025 for Innovation and Operations, citing new syringe line, automation and sustainability improvements.
Company representatives presented site developments and participated in the DCAT Member Company Announcement Forum and DCAT Week networking.
Company participation at the CPHI industry conference and exhibition.
Company participation at BIO International Convention 2025.
Project delivering formulation, process development and prototype clinical batch for an oncology drug in collaboration with a university and public funding.
Summary of technical and project milestones in 2023 including new syringe line installation, RABS implementation, FAT and mock-up activities.
Selected as a Top 10 finalist in FOYA 2025 for Innovation and Operations, citing new syringe line, automation and sustainability improvements.